Literature DB >> 10217503

Characterization of a haemolytic factor from Candida albicans.

Toshihiko Watanabe1, Mari Takano1, Mariko Murakami1, Hironori Tanaka1, Atsushi Matsuhisa1, Noriko Nakao1, Takeshi Mikami1, Masuko Suzuki2, Tatsuji Matsumoto1.   

Abstract

The culture supernatant of Candida albicans promoted the disruption of human red blood cells (RBCs). The haemolytic activity was detected in a sugar-rich fraction (about 200 kDa) from Sephacryl S-100 chromatography. As the haemolytic activity was adsorbed by concanavalin A-Sepharose, the haemolytic factor may be a mannoprotein. The activity was inactivated by periodate oxidation, indicating that the sugar moiety of the mannoprotein played an important role in the haemolysis. The structure of the sugar moiety of the mannoprotein was identified as a cell-wall mannan by 1H-NMR analysis, and purified C. albicans mannan promoted the disruption of RBCs. The binding of mannan to RBCs was demonstrated by flow cytometric analysis and was inhibited by the addition of band 3 protein inhibitor, 4,4'-diisothiocyanatostilbene-2,2'-disulfonic acid (DIDS). The haemolysis caused by mannan was inhibited by DIDS, SITS (4-acetamido-4'-isothiocyanatostilbene-2,2'-disulfonic acid) and bis(sulfosuccinimidyl) suberate, but not by pyridoxal 5-phosphate. These results indicated that a mannoprotein released from C. albicans bound to the band 3 protein on RBCs, thereby promoting their disruption.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10217503     DOI: 10.1099/13500872-145-3-689

Source DB:  PubMed          Journal:  Microbiology        ISSN: 1350-0872            Impact factor:   2.777


  29 in total

1.  Iron acquisition from transferrin by Candida albicans depends on the reductive pathway.

Authors:  Simon A B Knight; Gaston Vilaire; Emmanuel Lesuisse; Andrew Dancis
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

2.  The Aspergillus fumigatus siderophore biosynthetic gene sidA, encoding L-ornithine N5-oxygenase, is required for virulence.

Authors:  Anna H T Hissen; Adrian N C Wan; Mark L Warwas; Linda J Pinto; Margo M Moore
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

3.  Hemolysis of erythrocytes by granulysin-derived peptides but not by granulysin.

Authors:  Qing Li; Chen Dong; Anmei Deng; Masao Katsumata; Ari Nakadai; Tomoyuki Kawada; Satoshi Okada; Carol Clayberger; Alan M Krensky
Journal:  Antimicrob Agents Chemother       Date:  2005-01       Impact factor: 5.191

Review 4.  Candida albicans cell wall proteins.

Authors:  W LaJean Chaffin
Journal:  Microbiol Mol Biol Rev       Date:  2008-09       Impact factor: 11.056

5.  Candida albicans specializations for iron homeostasis: from commensalism to virulence.

Authors:  Suzanne M Noble
Journal:  Curr Opin Microbiol       Date:  2013-10-10       Impact factor: 7.934

6.  Sub-inhibitory concentrations of antifungals suppress hemolysin activity of oral Candida albicans and Candida tropicalis isolates from HIV-infected individuals.

Authors:  Sukumaran Anil; Mohamed Hashem; Sajith Vellappally; Shankargouda Patil; H M H N Bandara; L P Samaranayake
Journal:  Mycopathologia       Date:  2014-08-21       Impact factor: 2.574

7.  Candida species exhibit differential in vitro hemolytic activities.

Authors:  G Luo; L P Samaranayake; J Y Yau
Journal:  J Clin Microbiol       Date:  2001-08       Impact factor: 5.948

Review 8.  Insights into Candida tropicalis nosocomial infections and virulence factors.

Authors:  M Negri; S Silva; M Henriques; R Oliveira
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-10-30       Impact factor: 3.267

9.  Hemolytic factor production by clinical isolates of Candida species.

Authors:  Daniel Favero; Luciana Furlaneto-Maia; Emanuele J G França; Helena Peggau Góes; Marcia Cristina Furlaneto
Journal:  Curr Microbiol       Date:  2013-09-19       Impact factor: 2.188

Review 10.  Surface glycans of Candida albicans and other pathogenic fungi: physiological roles, clinical uses, and experimental challenges.

Authors:  James Masuoka
Journal:  Clin Microbiol Rev       Date:  2004-04       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.